The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

被引:1
|
作者
Li, Shu-Jing [1 ]
Liu, An-Bu [2 ]
Yu, Yuan-Yuan [2 ]
Ma, Jin-Hai [1 ]
机构
[1] Ningxia Med Univ, Gen Hosp, Dept Pediat Med, Yinchuan, Ningxia, Peoples R China
[2] Ningxia Med Univ, Gen Hosp, Dept Emergency Med, Yinchuan, Ningxia, Peoples R China
关键词
non-alcoholic fatty liver disease (NAFLD); pyroptosis; NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome; gasdermin D (GSDMD); caspase; targeted therapy; NLRP3 INFLAMMASOME ACTIVATION; HEPATOCYTE PYROPTOSIS; HEPATIC STEATOSIS; CELL-DEATH; FIBROSIS; STEATOHEPATITIS; NASH; INHIBITOR; APOPTOSIS; LIPOTOXICITY;
D O I
10.3389/fcell.2024.1407738
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
    Gruzdev, Stanislav Konstantinovich
    Podoprigora, Irina Viktorovna
    Gizinger, Oksana Anatolievna
    ARCHIVES OF MICROBIOLOGY, 2024, 206 (02)
  • [22] Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
    Tanase, Daniela Maria
    Gosav, Evelina Maria
    Petrov, Daniela
    Jucan, Alina Ecaterina
    Lacatusu, Cristina Mihaela
    Floria, Mariana
    Tarniceriu, Claudia Cristina
    Costea, Claudia Florida
    Ciocoiu, Manuela
    Rezus, Ciprian
    DIAGNOSTICS, 2021, 11 (11)
  • [23] Probiotics as Potential Therapy in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD)
    Monserrat-Mesquida, Margalida
    Bouzas, Cristina
    Mascaro, Catalina M.
    Tejada, Silvia
    Sureda, Antoni
    FERMENTATION-BASEL, 2023, 9 (04):
  • [24] Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease
    Sun, Chao
    Fan, Jian-Gao
    Qiao, Liang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (03) : 5161 - 5179
  • [25] Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets
    Ding, Ya-Hui
    Ma, Yuan
    Qian, Lin-Yan
    Xu, Qiang
    Wang, Li-Hong
    Huang, Dong-Sheng
    Zou, Hai
    ONCOTARGET, 2017, 8 (36) : 60673 - 60683
  • [26] Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease
    Rodriguez-Antonio, Itzayana
    Lopez-Sanchez, Guillermo N.
    Uribe, Misael
    Chavez-Tapia, Norberto C.
    Nuno-Lambarri, Natalia
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (10) : 2720 - 2727
  • [27] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Jürgen Kurt Rockstroh
    Current HIV/AIDS Reports, 2017, 14 : 47 - 53
  • [28] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
    Bugianesi, E
    Marzocchi, R
    Villanova, N
    Marchesini, G
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1105 - 1116
  • [29] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Rockstroh, Juergen Kurt
    CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
  • [30] The role of bacterial overgrowth in patients with non-alcoholic fatty liver disease (NAFLD)
    Treiber, Gerhard
    Weigt, Jochen
    Kolfenbach, Sven
    Leodolter, Andreas
    Malfertheiner, Peter
    GASTROENTEROLOGY, 2006, 130 (04) : A823 - A823